Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults

  1. Frances H. Priddy
  2. Michael Williams
  3. Simon Carson
  4. Brittany Lavender
  5. Julia Mathieson
  6. Chris Frampton
  7. Nicole J. Moreland
  8. Reuben McGregor
  9. Georgia Williams
  10. Maia Brewerton
  11. Katie Gell
  12. James Ussher
  13. Graham Le Gros

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.vaccine.2022.07.009
  2. ScreenIT

    SciScore for 10.1101/2022.04.05.22273480: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsConsent: All participants provided written informed consent.
    IRB: Ethical approval and Māori consultation: The study was approved by the NZ Ministry of Health COVID-19 Emergency Response Health and Disability Ethics Committee (21/NTB/117).
    Sex as a biological variableEnrollment was enriched to ensure adequate representation of Māori, Pacific peoples, older adults ≥65 and women.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    The assay is a chemiluminescent microparticle immunoassay designed to detect IgG antibodies to the nucleocapsid (NC) protein of SARS-CoV-2 in serum and plasma from individuals who are suspected to have had COVID-19.
    detect IgG
    suggested: None
    Software and Algorithms
    SentencesResources
    Nucleocapsid IgG: Serum samples were analysed by Southern Community Laboratories in Dunedin NZ with the Abbott SARS-CoV-2 IgG assay according to the manufacturers’ instructions (Abbott Laboratories, Abbott Park USA).
    Abbott Laboratories
    suggested: None
    Anti-SARS CoV-2 Spike IgG: Serum samples were analysed by Southern Community Laboratories in Dunedin NZ with the Abbott SARS-CoV-2 IgG II Quant assay according to the manufacturers’ instructions (Abbott Laboratories, Abbott Park USA).
    Abbott
    suggested: (Abbott, RRID:SCR_010477)
    Statistical analysis: Statistical analyses were performed using SPSS v27 software.
    SPSS
    suggested: (SPSS, RRID:SCR_002865)
    Graphical representation of the data was performed using R (version 4.0.3) and RStudio (version 1.3.1093).
    RStudio
    suggested: (RStudio, RRID:SCR_000432)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    This study has several limitations. It does not assess vaccine efficacy as there was little or no transmission during the study period described here. Only short term data through 28 days after 2 doses for the BNT162b2 vaccine is included. Understanding the durability of immune responses in this cohort, and response to booster doses will be important to assess the vaccination programme and shape future policy. Cellular immune responses are likely to be critical for both durability and breadth of COVID-19 vaccine-induced protection and are not included in the current study. Comorbidities were assessed by medical history and did not distinguish the duration or severity of disease, or whether the condition was treated/controlled. Cardiac and pulmonary comorbidities were grouped according to COVID-19 categories and include several diseases with varying pathology which may have diluted any potential associations with a single condition. This study did not include severely immunocompromised populations. Use of a high throughput surrogate viral neutralisation assay allowed rapid analysis for both ancestral and VoC responses, however there is less published comparative neutralisation data with this assay. Vaccine antibody responses to the BNT162b2 were generally robust and consistent with international data in this COVID-19 naïve cohort with representation of key NZ and Pacific populations at risk for COVID-19 morbidity. Subsequent data on response to boosters, durability of response...

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2022.04.05.22273480 on medRxiv